Windtree Announces Issuance of Composition of Matter Patent for Dual Mechanism SERCA2a Activators by the US Patent and Trademark Office
Patent provides protection through late 2039 for drug candidates with potential to improve cardiac function in heart failure patients WARRINGTON, Pa. , Aug. 23, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on
This article is featured on another website.
Evox Therapeutics Appoints Douglas Treco, Ph.D., to Board of Directors
Utilizing our DeliverEX™ platform, we are engineering exosomes to deliver protein and nucleic acid-based therapeutics to treat life-threatening rare diseases. At Evox Therapeutics we are harnessing the natural targeting and delivery capabilities of exosomes to engineer an entirely novel class of biotherapeutics.
Evox Therapeutics Appoints Douglas Treco, Ph.D., to Board of Directors
Utilizing our DeliverEX™ platform, we are engineering exosomes to deliver protein and nucleic acid-based therapeutics to treat life-threatening rare diseases. At Evox Therapeutics we are harnessing the natural targeting and delivery capabilities of exosomes to engineer an entirely novel class of biotherapeutics.